AP2015008628A0 - Crenolanib for treating FLT3 mutated proliferativedisorders - Google Patents

Crenolanib for treating FLT3 mutated proliferativedisorders

Info

Publication number
AP2015008628A0
AP2015008628A0 AP2015008628A AP2015008628A AP2015008628A0 AP 2015008628 A0 AP2015008628 A0 AP 2015008628A0 AP 2015008628 A AP2015008628 A AP 2015008628A AP 2015008628 A AP2015008628 A AP 2015008628A AP 2015008628 A0 AP2015008628 A0 AP 2015008628A0
Authority
AP
ARIPO
Prior art keywords
proliferativedisorders
crenolanib
flt3 mutated
treating flt3
treating
Prior art date
Application number
AP2015008628A
Other languages
English (en)
Inventor
Vinay K Jain
Original Assignee
Arog Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51061430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2015008628(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arog Pharmaceuticals Llc filed Critical Arog Pharmaceuticals Llc
Publication of AP2015008628A0 publication Critical patent/AP2015008628A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Physiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2015008628A 2013-01-07 2013-10-14 Crenolanib for treating FLT3 mutated proliferativedisorders AP2015008628A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361749695P 2013-01-07 2013-01-07
PCT/US2013/064821 WO2014107209A2 (fr) 2013-01-07 2013-10-14 Crenolanib pour traiter des troubles prolifératifs à mutation flt3

Publications (1)

Publication Number Publication Date
AP2015008628A0 true AP2015008628A0 (en) 2015-08-31

Family

ID=51061430

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2015008628A AP2015008628A0 (en) 2013-01-07 2013-10-14 Crenolanib for treating FLT3 mutated proliferativedisorders

Country Status (31)

Country Link
US (7) US9101624B2 (fr)
EP (1) EP2941251B1 (fr)
JP (1) JP6288726B2 (fr)
KR (1) KR101885952B1 (fr)
CN (4) CN105555272A (fr)
AP (1) AP2015008628A0 (fr)
AU (1) AU2013371624B2 (fr)
BR (1) BR112015016282A2 (fr)
CA (1) CA2897445C (fr)
CL (1) CL2015001923A1 (fr)
CY (1) CY1120026T1 (fr)
DK (1) DK2941251T3 (fr)
EA (1) EA033910B1 (fr)
ES (1) ES2667958T3 (fr)
HK (1) HK1224211A1 (fr)
HR (1) HRP20180478T1 (fr)
HU (1) HUE038594T2 (fr)
IL (1) IL239802B (fr)
LT (1) LT2941251T (fr)
MX (1) MX369137B (fr)
NO (1) NO3019692T3 (fr)
NZ (1) NZ710720A (fr)
PE (1) PE20151525A1 (fr)
PH (1) PH12015501531A1 (fr)
PL (1) PL2941251T3 (fr)
PT (1) PT2941251T (fr)
RS (1) RS57076B1 (fr)
SG (2) SG10201705611PA (fr)
SI (1) SI2941251T1 (fr)
WO (1) WO2014107209A2 (fr)
ZA (1) ZA201505545B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6407504B2 (ja) 2012-09-21 2018-10-17 アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
MX2018010252A (es) * 2016-02-26 2019-01-31 Celgene Corp Inhibidores de idh2 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
AU2017332721B2 (en) * 2016-09-20 2023-11-09 Sara BUHRLAGE Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators
EA201991078A1 (ru) * 2016-11-02 2019-11-29 Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3
WO2018118598A1 (fr) 2016-12-23 2018-06-28 Arvinas, Inc. Composés et procédés pour la dégradation ciblée de polypeptides de kinase du foie fœtal
CN114828842A (zh) * 2019-10-21 2022-07-29 理森制药股份公司 用于治疗急性髓系白血病的包含dhodh抑制剂的组合物
WO2022019998A1 (fr) * 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Formes cristallines de crénolanib et leurs procédés d'utilisation
US20220047574A1 (en) * 2020-08-15 2022-02-17 Arog Pharmaceuticals, Inc. Crenolanib for treating pdgfr alpha mutated proliferative disorders
WO2022051429A1 (fr) 2020-09-02 2022-03-10 Daniel Choi Systèmes et procédés pour environnements de réalité augmentée et jetons
US11969420B2 (en) 2020-10-30 2024-04-30 Arog Pharmaceuticals, Inc. Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
JP2023063189A (ja) * 2021-10-22 2023-05-09 アログ・ファーマシューティカルズ・インコーポレイテッド 以前の治療に対して再発性／不応性のｆｌｔ３突然変異増殖性障害を治療するためのクレノラニブ

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
EP1017682A4 (fr) 1997-09-26 2000-11-08 Merck & Co Inc Nouveaux inhibiteurs de l'angiogenese
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
US6656942B2 (en) 2000-10-17 2003-12-02 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
AU2363902A (en) * 2000-10-31 2002-05-15 Ciba Sc Holding Ag Crystalline forms of fluvastatin sodium
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
US7101884B2 (en) 2001-09-14 2006-09-05 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (fr) 2001-09-14 2003-03-27 Merck & Co., Inc. Inhibiteurs de tyrosine kinase
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
KR20090087139A (ko) 2001-10-30 2009-08-14 노파르티스 아게 Ｆｌｔ３ 수용체 티로신 키나아제 활성의 억제제로서의 스타우로스포린 유도체
AU2002360753B2 (en) 2001-12-27 2008-08-21 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
WO2004016597A2 (fr) 2002-08-14 2004-02-26 Vertex Pharmaceuticals Incorporated Inhibiteurs de la proteine kinase et leurs utilisations
EP1539754A4 (fr) 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic Quinolinones de benzimidazole et leurs utilisations
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
EP1566379A4 (fr) 2002-10-29 2005-11-09 Kirin Brewery DERIVES DE QUINOLINE ET DE QUINAZOLINE INHIBANT L'AUTOPHOSPHORYLATION DE Flt3 ET COMPOSITIONS MEDICALES LES CONTENANT
JP2006511616A (ja) 2002-11-13 2006-04-06 カイロン コーポレイション 癌の処置方法およびその関連方法
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
US7226919B2 (en) 2002-12-18 2007-06-05 Vertex Pharmaceuticals Inc. Compositions useful as inhibitors of protein kinases
NZ543714A (en) 2003-06-24 2009-06-26 Pfizer Prod Inc Processes for the preparation of 1-[(benzoimidazol-1yl)quinolin-8-yl]piperidin-4-ylamine derivatives
ATE444294T1 (de) * 2005-10-28 2009-10-15 Irm Llc Verbindungen und zusammensetzungen als proteinkinaseinhibitoren
WO2012052757A1 (fr) * 2010-10-20 2012-04-26 Astrazeneca Ab Procédé de sélection de patients selon leur phénotype tumoral
CN104080461A (zh) * 2011-11-30 2014-10-01 雪松-西奈医学中心 靶向微小rna mir-409-5p、mir-379和mir-154*来治疗前列腺癌骨转移和耐药性肺癌
JP6407504B2 (ja) * 2012-09-21 2018-10-17 アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法
JP6042157B2 (ja) 2012-09-26 2016-12-14 アログ・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニーＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，ＬＬＣ 変異型ｃ−ｋｉｔの阻害方法
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado

Also Published As

Publication number Publication date
IL239802A0 (en) 2015-08-31
HRP20180478T1 (hr) 2018-06-15
CN110200970A (zh) 2019-09-06
EP2941251A4 (fr) 2016-08-24
CL2015001923A1 (es) 2016-01-15
SG11201505327SA (en) 2015-08-28
US20160303109A1 (en) 2016-10-20
BR112015016282A2 (pt) 2017-07-11
EP2941251A2 (fr) 2015-11-11
US20200390756A1 (en) 2020-12-17
PL2941251T3 (pl) 2018-07-31
US20180015081A1 (en) 2018-01-18
IL239802B (en) 2020-06-30
EA201591290A2 (ru) 2016-03-31
PH12015501531B1 (en) 2015-09-21
US20190183879A1 (en) 2019-06-20
PE20151525A1 (es) 2015-10-23
KR101885952B1 (ko) 2018-08-06
MX2015008777A (es) 2015-11-13
US9393240B2 (en) 2016-07-19
ES2667958T3 (es) 2018-05-16
US9101624B2 (en) 2015-08-11
CN109966292A (zh) 2019-07-05
JP6288726B2 (ja) 2018-03-07
AU2013371624A1 (en) 2015-08-20
MX369137B (es) 2019-10-30
DK2941251T3 (en) 2018-03-26
PT2941251T (pt) 2018-03-23
CN105555272A (zh) 2016-05-04
CA2897445C (fr) 2019-04-30
EA033910B1 (ru) 2019-12-09
LT2941251T (lt) 2018-04-10
NZ710720A (en) 2020-06-26
RS57076B1 (sr) 2018-06-29
CN112138010A (zh) 2020-12-29
SG10201705611PA (en) 2017-08-30
ZA201505545B (en) 2016-10-26
PH12015501531A1 (en) 2015-09-21
EP2941251B1 (fr) 2018-03-07
JP2016508148A (ja) 2016-03-17
HK1224211A1 (zh) 2017-08-18
WO2014107209A2 (fr) 2014-07-10
CA2897445A1 (fr) 2014-07-10
US20140194464A1 (en) 2014-07-10
AU2013371624B2 (en) 2018-02-08
SI2941251T1 (en) 2018-06-29
US20220409610A1 (en) 2022-12-29
EA201591290A3 (ru) 2016-07-29
CY1120026T1 (el) 2018-12-12
US9801870B2 (en) 2017-10-31
NO3019692T3 (fr) 2018-06-16
US10213423B2 (en) 2019-02-26
US11458131B2 (en) 2022-10-04
US11007188B2 (en) 2021-05-18
HUE038594T2 (hu) 2018-10-29
US20150238479A1 (en) 2015-08-27
KR20150141930A (ko) 2015-12-21

Similar Documents

Publication Publication Date Title
HRP20180478T1 (hr) Crenolanib za liječenje flt3 mutiranih proliferativnih poremećaja
GB201312991D0 (en) Process
GB201307334D0 (en) Process
HK1220983A1 (zh) 方法
GB201321440D0 (en) Process
GB201416005D0 (en) Process
GB201322454D0 (en) Process
GB201421428D0 (en) Process
GB201401963D0 (en) Process
PL2941584T3 (pl) Środki chwytające
GB201318888D0 (en) Process
GB201421426D0 (en) Process
GB201401922D0 (en) Process
GB201322273D0 (en) Process
GB201314334D0 (en) Process
GB201302441D0 (en) Process
GB201320869D0 (en) Process
GB201307327D0 (en) Process
GB201300073D0 (en) Process
GB2520796B (en) Process
GB201323151D0 (en) Process
GB201307951D0 (en) Process
GB201316253D0 (en) Process
GB201418099D0 (en) Process
GB201319357D0 (en) Process